Homology Medicines

Homology Medicines, Inc. operates as a clinical-stage genetic medicines company with a focus on developing treatments for rare diseases by addressing the root cause of the illness. Founded in 2015, the company was incubated with seed investment from 5AM Ventures' company creation engine, the 4:59 Initiative. The firm's scientific foundation rests on the pioneering research of Dr. Saswati Chatterjee, a virologist from the City of Hope National Medical Center. Dr. Chatterjee's work in the early 1990s led to the discovery of a family of 15 adeno-associated viruses (AAVs) derived from human hematopoietic stem cells (AAVHSCs), which form the basis of the company's proprietary technology platform. Homology holds an exclusive worldwide license for this platform.

The company's core technology leverages a suite of 15 proprietary human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs). These vectors are utilized for in vivo delivery of genetic medicines through two primary modalities: traditional gene therapy and a nuclease-free gene editing process. Unlike nuclease-based platforms like CRISPR, Homology's gene editing technology, called AMEnDR (AAV-Mediated Editing by Directed Homologous Recombination), utilizes the cell's natural DNA repair pathway of homologous recombination. This method is designed for high precision, aiming to correct or edit gene mutations without making cuts to the DNA, thus avoiding unintended on-target insertions/deletions or off-target genotoxicity. The business model centers on the research, development, and eventual commercialization of these therapies. A key part of its strategy involved establishing its own 25,000-square-foot manufacturing facility to control the production of its clinical trial supplies.

Homology's product pipeline has targeted rare genetic disorders with significant unmet needs. Key clinical programs have included HMI-102, a gene therapy for adults with phenylketonuria (PKU), and HMI-103, a gene editing candidate for the same condition, which entered a Phase 1 clinical trial. Another significant candidate is HMI-203, a gene therapy for Hunter syndrome (MPS II). The company has also explored a GTx-mAb platform, using its AAVHSCs to enable one-time in vivo production of therapeutic antibodies. In November 2023, Homology Medicines announced a definitive merger agreement with Q32 Bio, an all-stock transaction. Following the merger, which closed in March 2024, Homology discontinued the development of its R&D programs to explore strategic alternatives for its assets, while pre-merger Homology stockholders received contingent value rights (CVRs) for potential proceeds from the disposition of these legacy assets.

Keywords: gene editing, gene therapy, rare diseases, AAV vectors, homologous recombination, phenylketonuria (PKU), Hunter syndrome, AAVHSC, clinical-stage, genetic medicines